Biology of hepatocellular carcinoma

Annals of Surgical Oncology

Volumn 15, Issue 4, 2008, Pages 962-971

  Pang, Roberta W C ^a   Joh, Jae Won ^b   Johnson, Philip J ^c   Monden, Morito ^d   Pawlik, Timothy M ^e   Poon, Ronnie T P ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d OSAKA UNIVERSITY   (Japan)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Biological factors; Biomarkers; Gene expression; Hepatocellular; Molecular

Indexed keywords

ALPHA FETOPROTEIN; ANGIOGENIC FACTOR; ANGIOPOIETIN; BIOLOGICAL FACTOR; BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN; GLYPICAN 3; LECTIN; TUMOR MARKER; VASCULOTROPIN;

ANGIOGENESIS; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; GENE EXPRESSION; HUMAN; LECTIN BINDING; LIVER CELL CARCINOMA; METASTASIS; MOLECULAR BIOLOGY; PROGNOSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS;

EID: 40549100994     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9730-z     Document Type: Conference Paper

References (122)

1. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 3:271-85
2. Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001; 234:63-70
3. Poon RT, Fan ST, Tsang FH, et al. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 2002; 235:466-486
4. Pang R, Tse E, Poon RT. Molecular pathways in hepatocellular carcinoma. Cancer Lett 2006; 240:157-69
5. Brechot C, Pourcel C, Louise A, et al. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature 1980; 286:533-5
6. Wang J, Chenivesse X, Henglein B, et al. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature 1990; 343:555-7
7. Chami M, Gozuacik D, Saigo K, et al. Hepatitis B virus-related insertional mutagenesis implicates SERCA1 gene in the control of apoptosis. Oncogene 2000; 19:2877-86
8. Minami M, Daimon Y, Mori K, et al. Hepatitis B virus-related insertional mutagenesis in chronic hepatitis B patients as an early drastic genetic change leading to hepatocarcinogenesis. Oncogene 2005; 24:4340-8
9. Feitelson MA, Duan LX. Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma. Am J Pathol 1997; 150:1141-57
10. Chirillo P, Falco M, Puri P, et al. Hepatitis B virus pX activates NF-kappa B-dependent transcription through a Raf-independent pathway. J Virol 1996; 700:641-6
11. Henkler F, Lopes AR, Jones M, et al. Erk-independent partial activation of AP-1 sites by the hepatitis B virus HBx protein. J Gen Virol 1998; 79:2737-42
12. Wang XW, Forrester K, Yeh H, et al. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci USA 1994; 91:2230-4
13. Pang R, Yuen J, Yuen MF, et al. PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene 2004; 23:4182-6
14. Pang R, Lee TK, Poon RT, et al. Pin1 interacts with a specific Serine-Proline motif in HBx to promote hepatocarcinogenesis. Gastroenterology 2007;132:1088-103
15. Becker SA, Lee TH, Butel JS, et al. Hepatitis B virus X protein interferes with cellular DNA repair. J Virol 1998; 72:266-72
16. El-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001; 5:87-207
17. Smela ME, Currier SS, Bailey EA, et al. The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis. Carcinogenesis 2001; 22:535-45
18. Shen HM, Ong CN. Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutat Res 1996; 366:23-44
19. Bressac B, Kew M, Wands J, et al. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350:429-31
20. Sell S, Hunt JM, Dunsford HA, et al. Synergy between hepatitis B virus expression and chemical hepatocarcinogens in transgenic mice. Cancer Res 1991; 51:1278-85
21. Ghebranious N, Sell S. The mouse equivalent of the human p53ser249 mutation p53ser246 enhances aflatoxin hepatocarcinogenesis in hepatitis B surface antigen transgenic and p53 heterozygous null mice. Hepatology 1998; 27:967-73
22. Kwun HJ, Jung EY, Ahn JY, et al. p53-dependent transcriptional repression of p21(waf1) by hepatitis C virus NS3. J Gen Virol 2001; 82:2235-41
23. Ghosh AK, Steele R, Meyer K, et al. Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. J Gen Virol 1999; 80:1179-83
24. Lee MN, Jung EY, Kwun HJ, et al. Hepatitis C virus core protein represses the p21 promoter through inhibition of a TGF-beta pathway. J Gen Virol 2002; 83:2145-51
25. Ray RB, Lagging LM, Meyer K, et al. Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. Virus Res 1995; 37:209-20
26. Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4:1065-7
27. Marusawa H, Hijikata M, Chiba T, et al. Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF-kappaB activation. J Virol 1999; 73:4713-20
28. Yeh CN, Lee WC, Chen MF. Hepatic resection and prognosis for patients with hepatocellular carcinoma larger than 10 cm: two decades of experience at Chang Gung memorial hospital. Ann Surg Oncol 2003; 10:1070-6
29. O'Suilleabhain CB, Poon RT, Yong JL, et al. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg 2003; 90:325-31
30. Johnson PJ, Williams R. Serum alpha-fetoprotein estimations and doubling time in hepatocellular carcinoma: Influence of therapy and possible value in early detection. J Nat Cancer Inst 1980; 64:1329-32
31. Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clinics in Liver Disease, ed. Di Bisceglie A. WB Saunders, Philadelphia, 2001; 5:p145-59
32. Sherman M. Alphafetoprotein: an obituary. J Hepatol 2001; 34:603-5
33. Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006; 12:1175-81
34. Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta 2001; 313:15-9
35. Yuen MF, Lai CL. Serological markers of liver cancer. Best Pract Res Clin Gastroenterol 2005; 19:91-9
36. Johnson PJ, Poon TCW, Hjelm NM, et al. Glycan composition of serum alpha-fetoprotein in patients with hepatocellular carcinoma and non-seminomatous germ cell tumour. Br J Cancer 1999; 81:1188-95
37. Johnson PJ, Poon TC, Hjelm NM, et al. Structures of disease-specific serum alpha-fetoprotein isoforms. Br J Cancer 2000; 83:1330-7.
38. Johnson PJ, Leung N, Cheng P, et al. "Hepatoma-specific" alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease. Br J Cancer 1997; 75:236-40.
39. Poon TC, Mok TS, Chan AT, et al. Quantification and utility of monosialylated alpha-fetoprotein in the diagnosis of hepatocellular carcinoma with nondiagnostic serum total alpha-fetoprotein. Clin Chem 2002; 48:1021-7
40. Taketa K, Endo Y, Sekiya C, et al. A collaborative study for the evaluation of lectin-reactive alpha-fetoprotein in early detection of hepatocellular carcinoma. Cancer Res 1993; 53:5419-23
41. Hayashi K, Kumada T, Nakano S, et al. Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am J Gastroenterol 1999; 94:3028-33
42. Ono M, Ohat H, Ohhira M. Measurement of immunoreactive prothrombin precursor and vitamin-K dependent gamma-carboxylation in human hepatocellular tissues: decreased carboxylation of prothrombin precursor as a cause of des-gamma-carboxyprothrombin synthesis. Tumour Biol 1990; 11:319-26
43. Weitz IC, Liebman HA. Dex-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma. Hepatology 1993; 18:990-7
44. Nomura F, Ishijima M, Horikoshi A, et al. Determination of serum des-gamma-carboxyprothrombin levels in patients with small-sized hepatocellular carcinoma. Comparison of the conventional enzyme immunoassay and two modified methods. Am J Gastroenterol 1996; 91:1380-3
45. Shimauchi Y, Tanaka M, Kuromatsu R, et al. A simultaneous monitoring of Lens culinaris agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients. Oncol Rep 2000; 7:249-56
46. Ishii M, Gama H, Chida N, et al. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol 2000; 95:1036-40
47. Okuda H, Nakanishi T, Takatsu K et al. Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein alone and those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol 2001; 16:1290-6.
48. Hamamura K, Shiratori Y, Shiina S, et al. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein. Cancer 2000; 88:1557-64.
49. Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest 2001; 108:497-501
50. Nakatsura T, Yoshitake Y, Senju S, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003; 306:16-25
51. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125:89-97
52. Hippo Y, Watanabe K, Watanabe A, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004; 64:2418-23.
53. Cheung ST, Wong SY, Leung KL, et al. Granulin-epithelin precursor overexpression promotes growth and invasion of hepatocellular carcinoma. Clin Cancer Res 2004; 10:7629-36
54. Poon TC, Yip TT, Chan AT, et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 2003; 49:752-60.
55. Schwegler EE, Cazares L, Steel LF, et al. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology 2005; 41:634-42.
56. Ward DG, Cheng Y, N'kontchou G, et al. Preclinical and post-treatment changes in the HCC-associated serum proteome. Br J Cancer 2006; 95:1379-83.
57. Belghiti J, Panis Y, Farges O, et al. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 1991; 214:114-7
58. Poon RT, Fan ST, Lo CM, et al. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 1999; 229:216-22
59. Klintmalm GB. Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg 1998; 228:479-90
60. Marsh JW, Dvorchik I, Subotin M, et al. The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology 1997; 26:444-50
61. Izumi R, Shimizu K, Ii T et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology 1994; 106:720-7
62. Yamanaka N, Okamoto E, Toyosaka A, et al. Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis. Cancer 1990; 65:1104-10
63. The Liver Cancer Study Group of Japan. Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 1994; 74:2772-80
64. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28:751-5
65. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19:329-38
66. Liver (Including intrahepatic bile ducts). In: Green F, Page D, I. F, et al, eds. AJCC Cancer Staging Handbook. New York: Springer; 2002:131-44
67. Kawarada Y, Ito F, Sakurai H, et al. Surgical treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol 1994; 33 Suppl:S12-7
68. Pawlik TM, Poon RT, Abdalla EK, et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005; 140:450-7.
69. Kosuge T, Makuuchi M, Takayama T, et al. Long-term results after resection of hepatocellular carcinoma: experience of 480 cases. Hepatogastroenterology 1993; 40:328-32
70. Poon RT, Fan ST, Wong J. Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. J Am Coll Surg 2002; 194:592-602
71. Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005; 11:1086-92
72. Tsai TJ, Chau GY, Lui WY, et al. Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery 2000; 127:603-8
73. Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33:1080-6
74. Vauthey JN, Klimstra D, Franceschi D, et al. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am J Surg 1995; 169:28-34
75. Ng KK, Vauthey JN, Pawlik TM, et al. Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 2005; 12:364-73
76. Vauthey JN, Lauwers GY, Esnaola NF et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002; 20:1527-36
77. Ikai I, Yamamoto Y, Yamamoto N, et al. Results of hepatic resection for hepatocellular carcinoma invading major portal and/or hepatic veins. Surg Oncol Clin North Am 2003; 12:65-75
78. Pawlik TM, Poon RT, Abdalla EK, et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 2005; 137:403-10
79. Poon RT, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000; 232:10-24.
80. Murgita RA, Goidl EA, Kontianen S, et al. Alpha-Fetoprotein induces suppressor T cells in vitro. Nature 1977; 267:257-9
81. Yachnin S, Soltani K, Lester EP. Further studies on the mechanism of suppression of human lymphocyte transformation by human alpha fetoprotein. J Allergy Clin Immunol 1980; 65:127-35
82. Shirabe K, Shimada M, Kajiyama K, et al. Clinicopathologic features of patients with hepatocellular carcinoma surviving >10 years after hepatic resection. Cancer 1998; 83:2312-6
83. Bilimoria MM, Lauwers GY, Doherty DA, et al. Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch Surg 2001; 136:528-35
84. Yamanaka N, Tanaka T, Tanaka W, et al. Correlation of hepatitis virus serologic status with clinicopathologic features in patients undergoing hepatectomy for hepatocellular carcinoma. Cancer 1997; 79:1509-15
85. Haratake J, Takeda S, Kasai T, et al. Predictable factors for estimating prognosis of patients after resection of hepatocellular carcinoma. Cancer 1993; 72:1178-83
86. Pawlik TM, Poon RT, Abdalla EK, et al. Hepatitis serology predicts tumor and liver-disease characteristics but not prognosis after resection of hepatocellular carcinoma. J Gastrointest Surg 2004; 8:794-804
87. Ntzani EE, Ioannidis JPA. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet 2003; 362:1439-44
88. Chiu JH, Kao HL, Wu LH, et al. Prediction of relapse or survival after resection in human hepatomas by DNA flow cytometry. J Clin Invest 1992; 89:539-45
89. Ng IOL, Lai ECS, Fan ST, et al. Prognostic significance of proliferating cell nuclear antigen expression in hepatocellular carcinoma. Cancer 1994; 73:2268-74
90. Suda T, Isokawa O, Aoyagi Y, et al. Quantitation of telomerase activity in hepatocellular carcinoma: a possible aid for a prediction of recurrent diseases in the remnant liver. Hepatology 1998; 27:402-6
91. Hayashi H, Sugio K, Matsumata T, et al. The clinical significance of p53 gene mutation in hepatocellular carcinoma from Japan. Hepatology 1995; 22:1702-7
92. Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003; 9:416-23
93. Iizuka N, Oka M, Yamada-Okabe H, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003; 361:923-9
94. Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004; 40:667-76.
95. Kurokawa Y, Matoba R, Takemasa I, et al. Molecular-based prediction of early recurrence in hepatocellular carcinoma. J Hepatol 2004; 41:284-91.
96. Kurokawa Y, Matoba R, Nagano H, et al. Molecular prediction of response to 5-fluorouracil and interferon-alpha combination chemotherapy in advanced hepatocellular carcinoma. Clin Cancer Res 2004; 10:6029-38
97. Lee JS, Thorgeirsson SS. Comparative and integrative functional genomics of HCC. Oncogene 2006; 25:3801-9
98. Cheung ST, Chen XY, Guan XY, et al. Identify metastasis-associated genes in hepatocellular carcinoma through clonality delineation for multinodular tumor. Cancer Res 2002; 62:4711-21
99. Smith MW, Yue ZN, Geiss GK, et al. Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma. Cancer Res 2003; 63:859-64
100. Patil MA, Chua MS, Oan KH, et al. An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene 2005; 24:3737-47
101. Yao DF, Wu XH, Zhu Y, et al. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2005; 4:220-6
102. Poon RT, Ng IO, Lau C, et al. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 2002; 20:1775-85
103. Sun HC, Tang ZY, Li XM, et al. Microvessel density of hepatocellular carcinoma: its relationship with prognosis. Cancer Res Clin Oncol 1999; 125:419-26
104. Uemori EN, Ferrara N, Bauer EA, et al. Vascular endothelial growth factor induces interstitial collagenase in human endothelial cells. J Cell Physiol 1992; 153:557-62
105. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19:1207-25
106. Chow NH, Hsu PI, Lin XZ, et al. Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study. Hum Pathol 1997; 28:698-703
107. Li XM, Tang ZY, Zhou G, et al. Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 1998; 17:13-17
108. Poon RT, Ng IO, Lau C, et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 2001; 233:227-35
109. Poon RT, Ho JW, Tong CS, et al. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004; 91:1354-60
110. Ho J, Pang RW, Lau C, et al. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology 2006; 44:836-43
111. Shimamura T, Saito S, Morita K, et al. Detection of vascular endothelial growth factor and its receptor expression in human hepatocellular carcinoma biopsy specimens. J Gastroenterol Hepatol 2000; 15:640-6
112. El-Assal ON, Yamanoi A, Soda Y, et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 1998; 27:1554-62
113. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999; 18:5356-62
114. Mituha N, Shimizu N, Ohtsuka M, et al. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 2003; 37:1105-13
115. Zhang ZL, Liu ZS, Sun Q. Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma. World J Gastroenterol 2006; 12:4241-5
116. Tanaka S, Sugimachi K, Yamashita Y. Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. Hepatology 2002; 35:861-7
117. El-Assal ON, Yamanoi A, Ono T, et al. The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma, Clin Cancer Res 2001; 7:1299-305
118. Morinaga S, Yamamoto Y, Noguchi Y, et al. Platelet-derived endothelial cell growth factor (PD-ECGF) is up-regulated in human hepatocellular carcinoma (HCC) and the corresponding hepatitis liver. Hepatogastroenterology 2003; 50:1521-6
119. Poon RT, Lau CP, Ho J, et al. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res 2003; 9:5339-45
120. Tang TC, Poon RT, Lau CP, et al. Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. World J Gastroenterol 2005; 11:1896-902
121. Hisai H, Kato J, Kobune M, et al. Increased expression of angiogenin in hepatocellular carcinoma in correlation with tumor vascularity. Clin Cancer Res 2003; 9:4852-9
122. Pang R, Poon RT. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 2006; 242:151-67